<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Watanabe M</submitter><funding>Grants-In-Aid for Scientific Research</funding><funding>the Environmental Restoration and Conservation Agency</funding><pagination>169</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6126416</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for exacerbation within a short duration.&lt;h4>Methods&lt;/h4>This prospective observational study evaluated the serum sST2 levels of 104 asthmatic patients who were treated by a lung disease specialist with follow-ups for 3 months.&lt;h4>Results&lt;/h4>High serum sST2 levels (> 18 ng/ml) predicted severe asthma exacerbation within 3 months. Serum sST2 levels correlated positively with asthma severity (treatment step), airway H&lt;sub>2&lt;/sub>O&lt;sub>2&lt;/sub> levels, and serum IL-8 levels. High serum sST2 levels and blood neutrophilia (> 6000 /μl) were </pubmed_abstract><journal>Respiratory research</journal><pubmed_title>Serum sST2 levels predict severe exacerbation of asthma.</pubmed_title><pmcid>PMC6126416</pmcid><funding_grant_id>KAKENHI; No. 15K09189</funding_grant_id><pubmed_authors>Sada M</pubmed_authors><pubmed_authors>Yokoyama T</pubmed_authors><pubmed_authors>Ogawa Y</pubmed_authors><pubmed_authors>Tamura M</pubmed_authors><pubmed_authors>Takizawa H</pubmed_authors><pubmed_authors>Watanabe M</pubmed_authors><pubmed_authors>Honda K</pubmed_authors><pubmed_authors>Ishii H</pubmed_authors><pubmed_authors>Nakamoto K</pubmed_authors><pubmed_authors>Kurai D</pubmed_authors><pubmed_authors>Inui T</pubmed_authors><pubmed_authors>Saraya T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Serum sST2 levels predict severe exacerbation of asthma.</name><description>&lt;h4>Background&lt;/h4>Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for exacerbation within a short duration.&lt;h4>Methods&lt;/h4>This prospective observational study evaluated the serum sST2 levels of 104 asthmatic patients who were treated by a lung disease specialist with follow-ups for 3 months.&lt;h4>Results&lt;/h4>High serum sST2 levels (> 18 ng/ml) predicted severe asthma exacerbation within 3 months. Serum sST2 levels correlated positively with asthma severity (treatment step), airway H&lt;sub>2&lt;/sub>O&lt;sub>2&lt;/sub> levels, and serum IL-8 levels. High serum sST2 levels and blood neutrophilia (> 6000 /μl) were </description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Sep</publication><modification>2025-04-21T17:41:54.746Z</modification><creation>2019-03-26T23:55:13Z</creation></dates><accession>S-EPMC6126416</accession><cross_references><pubmed>30176857</pubmed><doi>10.1186/s12931-018-0872-2</doi></cross_references></HashMap>